Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
Intrinsic Value
Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. [ Read More ]
The intrinsic value of one
Beijing Konruns Pharmaceutical Co Ltd
stock under the Base Case scenario is
47.53
CNY.
Compared to the current market price of 30.57 CNY,
Beijing Konruns Pharmaceutical Co Ltd
is
Undervalued by 36%.
Beijing Konruns Pharmaceutical Co Ltd's market capitalization is 4.9B CNY.
Beijing Konruns Pharmaceutical Co Ltd stock price is 30.57 CNY.
Beijing Konruns Pharmaceutical Co Ltd stock price (30.57 CNY) is 36% less than its Intrinsic Value (47.53 CNY).
Beijing Konruns Pharmaceutical Co Ltd stock price (30.57 CNY) is 25% less than its DCF Value (40.66 CNY). Open DCF Valuation
Beijing Konruns Pharmaceutical Co Ltd stock price (30.57 CNY) is 44% less than its Relative Value (54.41 CNY). Open Relative Valuation
Beijing Konruns Pharmaceutical Co Ltd has upside potential of 46% compared to the average analyst price target.
Open Wall St Estimates
Beijing Konruns Pharmaceutical Co Ltd's Revenue has been growing by 0% per year for the last 3 years.
Beijing Konruns Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 8% to 5%.
Beijing Konruns Pharmaceutical Co Ltd's Revenue has grown by 9% over the past 12 months.
Beijing Konruns Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
Beijing Konruns Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 10% to 7%.
Beijing Konruns Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 5%.
Beijing Konruns Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Beijing Konruns Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Beijing Konruns Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Beijing Konruns Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
Beijing Konruns Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 5%. The company is efficient at transforming stockholders' equity into net income.
Beijing Konruns Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 20% per year over the next 3 years.
Beijing Konruns Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Beijing Konruns Pharmaceutical Co Ltd's short-term assets (1B CNY) exceed its short-term liabilties (323m CNY).
Beijing Konruns Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.05.
Beijing Konruns Pharmaceutical Co Ltd's long-term assets (4B CNY) exceed its long-term liabilties (721m CNY).
Beijing Konruns Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (807m CNY) than debt (141m CNY).
Beijing Konruns Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 5.34.
Valuation Backtest
Beijing Konruns Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Beijing Konruns Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Beijing Konruns Pharmaceutical Co Ltd
Balance Sheet Decomposition
Beijing Konruns Pharmaceutical Co Ltd
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 807.4m |
| Receivables | 336.6m |
| Other Current Assets | 85.9m |
| Non-Current Assets | 2.6B |
| Long-Term Investments | 984.4m |
| PP&E | 417.1m |
| Intangibles | 1.1B |
| Other Non-Current Assets | 47.2m |
| Current Liabilities | 323.4m |
| Accounts Payable | 83m |
| Accrued Liabilities | 32.2m |
| Short-Term Debt | 96.9m |
| Other Current Liabilities | 111.3m |
| Non-Current Liabilities | 397.5m |
| Long-Term Debt | 43.8m |
| Other Non-Current Liabilities | 353.7m |
Earnings Waterfall
Beijing Konruns Pharmaceutical Co Ltd
|
Revenue
|
954.1m
CNY
|
|
Cost of Revenue
|
-111.7m
CNY
|
|
Gross Profit
|
842.4m
CNY
|
|
Operating Expenses
|
-698.6m
CNY
|
|
Operating Income
|
143.8m
CNY
|
|
Other Expenses
|
22.7m
CNY
|
|
Net Income
|
166.4m
CNY
|
Free Cash Flow Analysis
Beijing Konruns Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Beijing Konruns Pharmaceutical Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Beijing Konruns Pharmaceutical Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Beijing Konruns Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Beijing Konruns Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Beijing Konruns Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Beijing Konruns Pharmaceutical Co Ltd
is 44.55 CNY
.
Shareholder Return
Price
Beijing Konruns Pharmaceutical Co Ltd
| Average Annual Return | -7.16% |
| Standard Deviation of Annual Returns | 13.45% |
| Max Drawdown | -59% |
| Market Capitalization | 4.9B CNY |
| Shares Outstanding | 156 491 377 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Beijing Konruns Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing and currently employs 473 full-time employees. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Beijing Konruns Pharmaceutical Co Ltd
stock under the Base Case scenario is
47.53
CNY.
Compared to the current market price of 30.57 CNY,
Beijing Konruns Pharmaceutical Co Ltd
is
Undervalued by 36%.
You don't have any saved screeners yet
